Volume s1-14, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Approximately nine-tenths of the cases of amebiasis observed by us clinically in California have responded satisfactorily to oral therapy with 4-carbamino-phenyl-arsonic acid ("carbarsone") as reported previously (1). The majority of infected individuals seen here, however, are cyst passers with or without acute or chronic symptoms. Of the remaining 10 per cent, most patients harbor motile forms of and are suffering usually from acute dysentery or diarrhea. In this latter group, refractory to carbarsone used orally, we studied the effects of giving carbarsone rectally in retention enemata, in combination with the same drug orally, or other amebacides used either orally or hypodermically. We are reporting upon a small number of patients representing the group most difficult to deal with therapeutically, in that severe symptoms found in some cases require persistent, vigorous therapeutic measures, while others show evidence of impaired liver or kidney function, and their treatment has to be modified accordingly. Many of these cases are complicated by secondary bacterial infections which seriously impede treatment of the amebiasis. Fortunately cases with motile amebae are not seen as frequently in California and are not so serious a therapeutic problem as in the tropics.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error